AMETHOPTERIN (METHOTREXATE) IN CONNECTIVE TISSUE DISEASE—PSORIASIS AND POLYARTHRITIS

BY

G. D. KERSLEY

Bath

Methotrexate (amethopterin), a folic acid reductase inhibitor, affects primarily the tissues that are growing most rapidly. When in prolonged contact with the cell, its interference with the supply of available folic acid reduces the DHN content and hence holds up preparation for mitosis and division. Apart from neoplastic cells, the rapid epidermal proliferation of psoriasis is particularly susceptible; after this the brunt of the attack falls on the endothelium of the oral mucosa and gastro-intestinal tract, the hair follicles, and later the blood-forming elements—especially the granulocytes. The drug is easily absorbed orally and the greater part is excreted in the urine within 12 hours. Impaired renal function potentiates its effect, pregnancy is a contraindication, and over-dosage should be treated with folic acid (Leucovorin).

Folic acid antagonists were first used in the treatment of psoriasis by Gubner, August, and Ginsberg (1951). Further reports on their use in this disease were made by Rees, Bennett, Hamlin, and Maibach (1964), and Ryan, Vickers, Salem, Callender, and Badenoch (1964), three deaths being reported by the former. Shrank and Blendis (1965) gave details of two cases in which methotrexate at least contributed to death, one from leucopenia and the other from duodenal haemorrhage. O'Brien, Van Scott, Black, Eisen, and Bunim (1962) reported sixteen cases of psoriatic arthritis, two of psoriasis and arthritis, and five of rheumatoid arthritis treated with parenteral methotrexate 25 mg. every 7 to 14 days. In thirteen of these eighteen cases the joints and the skin condition showed some improvement, but eleven developed anorexia, five leucopenia, and one alopecia. In all cases the toxic reactions subsided within 2 weeks of ceasing treatment.

Recently Haim, and Alroy (1967) reported deaths after 5 and 7 days respectively of 5·0 mg. methotrexate, plus steroids, apparently from leucopenia and sepsis. Burrows and Kelly (1967) recorded severe toxicity and leucopenia with recovery in 3 weeks after taking only 2·5 mg. for 4 days.

Present Investigations

A case of severe pustular psoriatic arthritis reacted so well to methotrexate, relapsing when the drug was stopped and improving again when it was restarted, that further investigation of its effect both on the psoriasis and arthritis was prompted.

Case Report

A man aged 52 years noticed stiffness after exercise at the age of 30 and had an attack of bilateral sciatica at age 37. In March, 1964, at the age of 48, he developed simultaneously severe psoriasis and arthritis of the right elbow and left shoulder.

When seen in August, 1964, he had a very severe generalized psoriasis, pustular psoriasis of the fingernails and toenails, and extremely swollen and partly subluxated knees and ankles. The neck and back were stiff but there was little pain. He had lost a stone in weight and his temperature rose to 101° F. at night. The erythrocyte sedimentation rate was 120 mm./hr., Hb 70 per cent., and rheumatoid factor tests negative.

He was immediately given ACTH 40 units daily, erythromycin, and imferon injections. The results were most disappointing, the haemoglobin dropping to 60 per cent. The white count was 5,000/cu. mm. with 78 per cent. polymorphs. He was transfused with packed red cells, and prednisolone rising to 15 mg./day was added, yet by November he was extremely ill. He was then given 4 mg. betamethasone (Betnesol), equivalent to approximately 35 mg. prednisolone, plus 2·5 mg. methotrexate on 5 days per week, and the ACTH was stopped. Improvement was dramatic and the medication was continued for 7 months, with very gradual reduction of the betamethasone to 2 mg., until June, 1965.

The patient was now a changed man. The erythrocyte sedimentation rate had fallen from 80 to 2 mm./hr., the Hb was 104 per cent., and the white cell count had changed from 8,800 to 6,400/cu. mm. He had, however,
gained too much weight and was walking with sticks. The psoriasis was well controlled and all infection had disappeared. The only trouble during the period had been a collapsed vertebra in February, 1965, which was treated satisfactorily with durabolin, calcium, a high protein diet, and (temporarily) a back support.

In the next 5 months the methotrexate was discontinued, but the Betnesol 2 mg. daily was maintained. At the end of this period both the arthritis and the psoriasis were again much worse and methotrexate 2-5 mg. daily was restarted with no other change in medication. Both joints and psoriasis again improved dramatically and in May, 1966, he was in very good condition except that the haemoglobin had risen to 122 per cent. The erythrocyte sedimentation rate was 2 mm./hr., and the white blood count 7,200/cu. mm. P32 was administered and the haemoglobin dropped to 102 per cent.

The methotrexate was then discontinued again, but by July, 1966, the psoriasis was again a serious problem and he has since been given methotrexate 2·5 mg. 3 days a week with continued good results.

In view of this patient's excellent progress, methotrexate has been tried in twelve other patients, including ten with psoriatic arthritis. The clinical results are summarized in the Table.

Seven of the ten cases of psoriasis showed a dramatic improvement in their skin lesions and one some benefit. In five of twelve cases the arthritis appeared to benefit greatly and in one there was some improvement. Only five, however, were completely free of toxic symptoms; the other seven all developed mouth ulcers. One also had diarrhoea and vomiting and one complained of loss of hair. In all cases the onset of toxic symptoms occurred within 7 days of starting treatment, but they all disappeared within a month of discontinuing the drug and in most cases within 10 days. In all cases regular complete blood counts were carried out and it is a striking fact that in no case was there any evidence of depression of red or white cell formation. Even during severe toxic reactions the only change in the white count was an occasional slight leucocytosis.

**Summary and Conclusion**

Ten cases of psoriatic polyarthritis and two other cases were treated with methotrexate. The psoriasis was improved in 80 per cent. and the joints in 50 per cent. Ulceration of the mouth occurred in 58 per cent. of those treated. None showed evidence of haemopoietic damage.

These results indicate that the frequency of toxic reactions and likely length of remission of symptoms is such that amethopterin is not suitable for routine use. Certain patients, however, tolerate the drug well and it may be valuable under careful supervision in selected severe cases of psoriatic arthritis.

**Table**

<table>
<thead>
<tr>
<th>Case No.</th>
<th>Diagnosis</th>
<th>First Course</th>
<th>Second Course</th>
<th>Toxic Reaction and Duration</th>
<th>Effect</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Average Dose (mg./day)</td>
<td>Duration (wks)</td>
<td>Average Dose (mg./day)</td>
<td>Duration (wks)</td>
</tr>
<tr>
<td>1</td>
<td>Psoriatic Arthritis</td>
<td>1·8</td>
<td>30</td>
<td>5</td>
<td>1·8</td>
</tr>
<tr>
<td>2</td>
<td>Psoriatic Arthritis</td>
<td>2·5</td>
<td>3</td>
<td>0</td>
<td>5·0</td>
</tr>
<tr>
<td>3</td>
<td>Psoriatic Arthritis</td>
<td>2·5</td>
<td>3</td>
<td>0</td>
<td>5·0</td>
</tr>
<tr>
<td>4</td>
<td>Psoriatic Arthritis</td>
<td>2-5</td>
<td>2</td>
<td>1</td>
<td>2·5</td>
</tr>
<tr>
<td>5</td>
<td>Psoriatic Arthritis</td>
<td>2·5</td>
<td>8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>Psoriatic Arthritis</td>
<td>2·5</td>
<td>5</td>
<td>2</td>
<td>2·5</td>
</tr>
<tr>
<td>7</td>
<td>Psoriatic Arthritis</td>
<td>5·0</td>
<td>3</td>
<td>0</td>
<td>2·5</td>
</tr>
<tr>
<td>8</td>
<td>Psoriatic Arthritis</td>
<td>2·5</td>
<td>2</td>
<td>0</td>
<td>5·0</td>
</tr>
<tr>
<td>9</td>
<td>Psoriatic Arthritis</td>
<td>5·0</td>
<td>8</td>
<td>1</td>
<td>5·0</td>
</tr>
<tr>
<td>10</td>
<td>Psoriatic Arthritis</td>
<td>5·0</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>Rheumatoid Arthritis</td>
<td>2·5</td>
<td>1</td>
<td>0</td>
<td>5·0</td>
</tr>
<tr>
<td>12</td>
<td>Systemic Lupus Erythematosus</td>
<td>2·5</td>
<td>7</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
The experience of Burrows and Kelly (1967) and of Haim and Alroy (1967) and the results in two of our patients (Cases 10 and 11) suggest that some persons are unduly sensitive to methotrexate; others, however, react extremely well to this drug even when used for a prolonged period (Cases 1 and 9).

REFERENCES


L'améthoptérine (Méthotrexate) dans les maladies du tissu conjonctif—psoriasis et polyarthrite

RÉSUMÉ

On traite par le Méthotrexate dix cas de polyarthrite psoriasique et deux autres cas. Le psoriasis regresa dans 80% des cas et l'atteinte articulaire dans 50%. Des ulcerations buccales apparurent dans 58% des cas traités. On n'observa pas de signes d'atteinte hématopoïétique.

Ces résultats montrent que la fréquence des réactions toxiques et la durée probable de régression des symptômes est telle que ce produit n'est pas à conseiller comme traitement régulier. Toutefois, certains malades tolèrent bien ce médicament et il pourrait être d'un grand secours dans des cas graves sélectionnés d'arthrite psoriasique.

L'expérience de Burrows et Kelly (1967) et de Haim et Alroy (1967) et les résultats obtenus chez deux de nos malades (cas 10 et 11) suggèrent que certains sujets sont particulièrement sensibles au Méthotrexate; d'autres cependant réagissent extrêmement bien à ce médicament, même utilisé pour un traitement prolongé (cas 1 et 9).

Ametopterina (Methotrexate) en las enfermedades del tejido conectivo—psoriasis y poliartritis

SUMARIO

Se trataron con Methotrexate diez casos de poliarritis psoriásica y dos otros casos. La psoriasis mejoró en un 80% de los casos y la afección articular en un 50%. Ulceraciones orales sobrevinieron en un 58 de los casos tratados. No se observaron signos de afección hematopoética.

Estos resultados muestran que la frecuencia de reacciones tóxicas y la duración probable de la regresión sintomática son tales que este producto no se puede aconsejar para un tratamiento regular. Sin embargo, ciertos enfermos le toleran bien y en casos graves y cuidadosamente escogidos su empleo puede ser útil.

La experiencia de Burrows y Kelly (1967) y la de Haim y Alroy (1967) y los resultados obtenidos con dos enfermos nuestros (casos 10 y 11) sugieren que algunos sujetos son particularmente sensibles a Methotrexate; otros, sin embargo, lo aguantan muy bien y a veces durante un tratamiento prolongado (casos 1 y 9).
A methotrexate (methotrexate) in connective tissue disease-psoriasis and polyarthritis.

G D Kersley

*Ann Rheum Dis* 1968 27: 64-66
doi: 10.1136/ard.27.1.64

Updated information and services can be found at:
http://ard.bmj.com/content/27/1/64.citation

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/